A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models

Planning any experiment includes issues such as how many samples are to be taken and their location given some predictor variable. Often a model is used to explain these data; hence including this formally in the design will be beneficial for any subsequent parameter estimation and modelling. A number of criteria for model oriented experiments, which maximise the information content of the collected data are available. In this paper we present a program, Optdes, to investigate the optimal design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models. Using the developed software the location of either a predetermined number of design points (exact designs) or together with the proportion of samples at each point (continuous designs) can be determined. Local as well as Bayesian designs can be optimised by either D- or A-optimality criteria. Although often the optimal design cannot be applied for practical reasons, alternative designs can be readily evaluated.

[1]  France Mentré,et al.  Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.

[2]  Anthony C. Atkinson,et al.  Optimum Experimental Designs , 1992 .

[3]  W. Busby,et al.  Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[4]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[5]  K. Chaloner,et al.  Optimal Bayesian design applied to logistic regression experiments , 1989 .

[6]  France Mentré,et al.  Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  J. W. Akitt.  Function Minimisation Using the Nelder and Mead Simplex Method with Limited Arithmetic Precision: The Self Regenerative Simplex , 1977, Comput. J..

[8]  Sandro Ridella,et al.  Minimizing multimodal functions of continuous variables with the “simulated annealing” algorithmCorrigenda for this article is available here , 1987, TOMS.

[9]  G. Bekey,et al.  A global optimization algorithm using adaptive random search , 1980 .

[10]  K. Chaloner.  Optimal Bayesian Experimental Design for Linear Models , 1984 .

[11]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[12]  David Z. D'Argenio,et al.  Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  France Mentré,et al.  Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  H. Wynn,et al.  Maximum entropy sampling and optimal Bayesian experimental design , 2000 .

[15]  A. Li,et al.  Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Jeffrey C. Lagarias,et al.  Convergence Properties of the Nelder-Mead Simplex Method in Low Dimensions , 1998, SIAM J. Optim..

[17]  A. Atkinson,et al.  Optimum Experimental Designs for Multinomial Logistic Models , 1999, Biometrics.

[18]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[19]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[21]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[22]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[23]  Y Wang,et al.  Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Douglas Faires,et al.  Numerical Analysis , 1981 .

[25]  Eric Walter,et al.  Identifiability of parametric models , 1987 .

[26]  L. Endrenyi.  Design of Experiments for Estimating Enzyme and Pharmacokinetic Parameters , 1981 .

[27]  G. W. Morgan,et al.  Kinetic Data Analysis, Design and Analysis of Enzyme and Pharmacokinetic Experiments , 1981 .

[28]  P. Whittle.  Some General Points in the Theory of Optimal Experimental Design , 1973 .

[29]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.